Cord blood stem cell therapy - Gamida Cell

Drug Profile

Cord blood stem cell therapy - Gamida Cell

Alternative Names: CordIn; NiCord; UC MSC; Umbilical cord blood stem cell therapy - Gamida Cell; Umbilical cord mesenchymal stem cells

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gamida-Cell
  • Developer Gamida-Cell; National Heart, Lung and Blood Institute
  • Class Antirheumatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Myelodysplastic syndromes; Haematological malignancies; Acute myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Haematological malignancies
  • Phase I/II Aplastic anaemia; Haemoglobinopathies; Myelodysplastic syndromes; Sickle cell anaemia; Thalassaemia
  • No development reported Autoimmune disorders; Metabolic disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral, Infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (Parenteral, Infusion)
  • 14 Jun 2017 National Heart, Lung, and Blood Institute plans a phase I/II trial for Aplastic anaemia and myelodysplastic syndromes in USA (NCT03173937)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top